Mar 19 |
Corvus Pharmaceuticals GAAP EPS of -$0.14 misses by $0.01
|
Mar 19 |
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
|
Mar 13 |
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
|
Mar 9 |
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully
|
Feb 12 |
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
|
Feb 8 |
Corvus lymphoma drug gets FDA orphan drug status
|
Feb 8 |
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
|
Feb 6 |
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
|
Jan 23 |
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
|
Jan 5 |
Individual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last week
|